大摩：维持药明生物(02269)“增持”评级 目标价63.1港元
摩根士丹利发布报告称，维持药明生物(02269)“增持”评级，目标价63.1港元。公司2023年业绩基本符合预期，包括经调整盈利46.99亿元人民币，收入170亿元人民币，升11.6%，扣除COVID因素，则收入同比增长37.7%。公司指引2024年收入增长为5%-10%，若扣除COVID因素则同比增长8%-14%。大摩认为若达高单位数增长是可行及坚实。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.